Darpp-32 and its truncated variant t-Darpp have antagonistic effects on breast cancer cell growth and herceptin resistance.

<h4>Background</h4>Herceptin (trastuzumab) is a humanized monoclonal antibody that is approved for the treatment of metastatic breast cancer patients whose tumors overexpress Her2 (erbB2/neu). Up to 70% of Her2-positive breast cancers demonstrate a response to Herceptin-based therapies,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Long Gu, Sarah Waliany, Susan E Kane
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2009
Materias:
R
Q
Acceso en línea:https://doaj.org/article/44da831265354ae09157b44d2cf221c9
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!